JAMA
Vol. 302 No. 24, pp. 2625-2722, December 23/30, 2009
http://jama.ama-assn.org/current.dtl

Letters
Adverse Events and Quadrivalent Human Papillomavirus Recombinant Vaccine
Vicky Debold; Eric Hurwitz
JAMA. 2009;302(24):2657.
Adverse Events and Quadrivalent Human Papillomavirus Recombinant Vaccine—Reply
John Iskander; Claudia Vellozzi; Barbara A. Slade
JAMA. 2009;302(24):2657-2658.
Efficacy Data and HPV Vaccination Studies
Norman W. Baylor; Melinda Wharton
JAMA. 2009;302(24):2658-2659.
Efficacy Data and HPV Vaccination Studies
Rebecca B. Perkins
JAMA. 2009;302(24):2659.
Efficacy Data and HPV Vaccination Studies—Reply
Charlotte Haug
JAMA. 2009;302(24):2659-2660.
Marketing and the HPV Vaccine
L. Stewart Massad
JAMA. 2009;302(24):2660.
Marketing and the HPV Vaccine
Marisol Betensky
JAMA. 2009;302(24):2660-2661.
Marketing and the HPV Vaccine—Reply
Sheila M. Rothman; David J. Rothman
JAMA. 2009;302(24):2661.